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SUMMARY
The cholinergic basal forebrain contributes to cortical activation and
receives rich innervations from the ascending activating system. It is
involved in the mediation of the arousing actions of noradrenaline and
histamine. Glutamatergic stimulation in the basal forebrain results in
cortical acetylcholine release and suppression of sleep. However, it is not
known to what extent the cholinergic versus non-cholinergic basal
forebrain projection neurones contribute to the arousing action of
glutamate. To clarify this question, we administered N-methyl-D-
aspartate (NMDA), a glutamate agonist, into the basal forebrain in intact
rats and after destruction of the cholinergic cells in the basal forebrain
with 192 immunoglobulin (Ig)G-saporin. In eight Han–Wistar rats with
implanted electroencephalogram/electromyogram (EEG/EMG) elec-
trodes and guide cannulas for microdialysis probes, 0.23 lg 192 IgG-
saporin was administered into the basal forebrain, while the eight control
animals received artiﬁcial cerebrospinal ﬂuid. Two weeks later, a
microdialysis probe targeted into the basal forebrain was perfused with
cerebrospinal ﬂuid on the baseline day and for 3 h with 0.3 mM NMDA on
the subsequent day. Sleep–wake activity was recorded for 24 h on both
days. NMDA exhibited a robust arousing effect in both the intact and the
lesioned rats. Wakefulness was increased and both non-REM and REM
sleep were decreased signiﬁcantly during the 3-h NMDA perfusion.
Destruction of the basal forebrain cholinergic neurones did not abolish
the wake-enhancing action of NMDA. Thus, the cholinergic basal
forebrain structures are not essential for the mediation of the arousing
action of glutamate.
INTRODUCTION
Projections from the brain stem reticular formation ascend
into the forebrain and stimulate the cortical activity via a
dorsal relay in the thalamus and a ventral one through the
hypothalamus and the basal forebrain (BF). The BF is both a
critical relay in the mediation of cortical arousal (Fuller et al.,
2011; Jones, 2005) and a key area in the regulation of the
sleep–wake cycle (Szymusiak, 1995). The BF inﬂuences
cortical activity via cholinergic, gamma-aminobutyric acid
(GABA)ergic and glutamatergic direct pathways projecting to
the cerebral cortex (Henny and Jones, 2008) and also
indirectly, e.g. via pathways projecting to the thalamus (Detari
et al., 1999). The cortical release of acetylcholine is
enhanced during cortical activation (Detari et al., 1999;
Szerb, 1967; Szymusiak, 1995). The rate of discharge of
the cholinergic BF cells is maximal during wakefulness (W)
and rapid eye movement (REM) sleep, i.e. when the cortical
electroencephalogram (EEG) is desynchronized (Hassani
et al., 2009). The wake-associated increase in the activity of
these cells is also related closely to the mechanism of
recovery sleep following a prolonged W period (Kalinchuk
et al., 2008; Porkka-Heiskanen et al., 1997). Some of the
non-cholinergic neurones also increase their activity during
W and REM sleep (Hassani et al., 2009). Cholinergic and
non-cholinergic neurones in the BF function jointly in the
control of cortical activation (Fuller et al., 2011).
Fibres from the ascending activating system (Fuller et al.,
2011; Jones, 2005; Szymusiak, 1995) innervating the BF
terminate on most cell types, making it difﬁcult to evaluate
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their speciﬁc roles. However, the function of the cholinergic
neurones has been addressed by using the immunotoxin 192
immunoglobulin (Ig)G-saporin (SAP) to destroy the choliner-
gic cells speciﬁcally (Pizzo et al., 1999). It has been found
that the cortical activation by both histamine and nora-
drenaline is mediated via the BF cholinergic cells (Lelkes
et al., 2013; Zant et al., 2012), whereas these neurones do
not seem to be important for the arousing action of hypocretin
(Blanco-Centurion et al., 2006).
Glutamatergic neurones form the backbone of the cortical-
activating and behavioural-arousal systems (Jones, 2005).
BF receives glutamatergic innervations from various areas,
including the cortex, the amygdala and some regions of the
brain stem (Fuller et al., 2011; Sarter and Bruno, 1999).
Glutamate (GLUT) receptors are expressed in the BF (De
Souza Silva et al., 2006; Martin et al., 1993), and local
application of GLUT agonists into the BF results in EEG
activation, W enhancement (Cape and Jones, 2000; Manfridi
et al., 1999; Wigren et al., 2007) and an increase in cortical
acetylcholine release. The amount of acetylcholine released
correlates with the gamma power in the EEG, indicating that
BF cholinergic neurones may participate in the mediation of
arousal (Fournier et al., 2004). However, both cholinergic
and non-cholinergic neurones in the BF are innervated by
glutamatergic ﬁbres and activated by GLUT agonists (Cape
and Jones, 2000; Hur et al., 2009), and it is not clear to what
extent BF cholinergic versus non-cholinergic cells contribute
to the mediation of the arousing effect of GLUT. The aim of
the present study was to clarify the role of BF cholinergic
neurones in the mediation of the arousing effect of GLUT on
cortical activity. We administered N-methyl-D-aspartate
(NMDA), a GLUT agonist locally into the BF, in the vicinity
of the horizontal diagonal band (HDB), substantia innominata
(SI) and magnocellular pre-optic nucleus (MCPO), and
recorded the sleep–wake activity before and after the
administration of NMDA in intact rats and also after selective
destruction of the BF cholinergic cells by means of a
microinjection of the immunotoxin SAP.
METHODS
Animals and surgery
Under general anaesthesia with isoﬂurane (FarmaPlus AS,
Oslo, Norway; induction: 3–5% in an induction chamber,
maintenance: 1.5% delivered by mask inhalation), after the
inﬁltration of 1% lidocaine (Orion Oy, Espoo, Finland) into the
tissues over the skull, male Han–Wistar rats (370–400 g;
n = 16; Harlan Laboratories, Venray, the Netherlands) were
implanted with EEG (gold-plated screws, epidurally over the
frontal and parietal cortices) and electromyogram (EMG)
electrodes (silver wires covered by Teﬂon, into the neck
muscles). A unilateral microdialysis guide cannula (CMA/11
Guide; CMA/Microdialysis, Stockholm, Sweden) was
implanted in such a way that the tip was located 2 mm
above the target area in the BF (HDB/SI/MCPO; AP = 0.3;
ML = 2.0; V = 6.5; Paxinos and Watson, 1998). After the
surgery, the rats were housed individually under conditions of
controlled temperature (22 + 1 °C) and light (lights on: 8:30–
20:30 hours) with access to food and water ad libitum. All
procedures were approved by the Ethics Committee for
Animal Experiments at the University of Helsinki and the
provincial Government of Uusimaa, Finland (ESAVI-5028-
04.10.07-2014), and were in accordance with the relevant
Finnish and European Union laws. All efforts were made to
minimize the number of animals used and their suffering.
Recording
The EEG and EMG signals were ampliﬁed, ﬁltered (high-
pass: 0.3 and 10 Hz for the EEG and EMG, respectively;
low-pass: 100 Hz) and sampled at 278 and 139 Hz for the
EEG and EMG, respectively. Vigilance states [W, non-REM
(NREM) and REM sleep] were scored manually in 4-s
epochs according to standard criteria, as described previ-
ously (Lelkes et al., 2013); in addition, power spectra values
were calculated by fast-Fourier transformation for consecu-
tive 4-s epochs with the aid of the Spike2 program version 6
(Cambridge Electronic Devices, Cambridge, UK) using the
script Sleepscore version 1.01. Vigilance-state-speciﬁc EEG
delta (1–4 Hz), low theta (4–6 Hz), high theta (6–9 Hz),
alpha (9–13 Hz) and beta (13–30 Hz) powers were
calculated.
Microdialysis and NMDA administration
Under isoﬂurane anaesthesia, microdialysis probes (CMA/
Microdialysis, Kista, Sweden; CMA 11, 6000 Da, membrane
length 2 mm, diameter 0.24 mm) were inserted through the
guide cannula into the HDB/SI/MCPO (AP = 0.3; ML = 2.0;
V = 8.5; Paxinos and Watson, 1998) at least 2 days before
the start of the ﬁrst experiment. The rats were then connected
to the microdialysis tubing (and also to the recording leads)
and remained connected continuously until the end of the
experiments. The microdialysis tubing was connected to a
microdialysis pump between 09:30 and 10:00 hours, and
continuous perfusion was started at 10:00 hours and termi-
nated at 20:00 hours, the tubing then being disconnected
from the microdialysis pump. Artiﬁcial cerebrospinal ﬂuid
(CSF; NaCl 147 mM; KCl 3 mM; CaCl2 1.2 mM; MgCl2
1.0 mM) or NMDA (Sigma-Aldrich, Co., St Louis, MO, USA;
0.3 mM, dissolved in CSF) was pumped through the micro-
dialysis probe (1 lL/min) according to the experimental
schedule (see below). This relatively long-lasting perfusion
prevented blocking of the probe and tubing.
Lesioning of BF cholinergic structures by administration
of the immunotoxin SAP
In eight rats, SAP (0.23 lg in 1 lL, ﬂow rate: 0.1 lL/min;
Chemicon International, Inc., Temecula, CA, USA; batch
#0703054253) was injected into the HDB/SI/MCPO as
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described previously (Kalinchuk et al., 2008). The eight
control (intact) rats received the same volume of vehicle.
Experimental schedule
After the surgery, SAP (n = 8, lesioned animals) or vehicle
[n = 8, control (intact) animals] was injected into the BF. Two
weeks later, after recovery and adaptation to the recording
conditions, the microdialysis probe targeted into the BF was
perfused with CSF during the period 10:00–20:00 hours on
the baseline day and with NMDA during the period 10:00–
13:00 hours, and then with CSF until the end of perfusion
(13:00–20:00 hours) on the subsequent NMDA day. The
sleep–wake activity was recorded for 24 h, starting at
10:00 hours on both days.
Histological veriﬁcation of probe locations and SAP
lesioning
After the ﬁnal experiment, the animals received a lethal dose
of pentobarbital [100 mg/kg; Mebunat intraperitoneally (i.p.);
Orion Pharma Oy, Espoo, Finland]. Ink was injected through
a modiﬁed microdialysis probe inserted into the guide
cannula. To verify only the probe location, the brain was
removed, stored at 80, cut, stained with Toluidine blue and
inspected visually, as described previously (Lelkes et al.,
2013; Fig. 1). In case of cholinergic lesion by SAP, the loss of
cells was veriﬁed by choline acetyltransferase (ChAT) stain-
ing. Under deep anaesthesia (100 mg/kg pentobarbital) the
animals were perfused transcardially with 0.9% saline
followed by 4% paraformaldehyde (PFA) in 0.1 M PBS, pH
7.4. The brains were then removed, submerged overnight in
4% PFA and then in 30% sucrose solution for 4 days, cut and
stained. The sample preparation and immunohistochemistry
with goat anti-ChAT antibody (Chemicon; AB144P, 1 : 250)
were performed as conducted by Borges et al. (2013). The
number of ChAT-positive cells on the SAP treated side was
compared to that on the untreated control side (Fig. 1).
Statistics
All statistical analyses were performed on 3-h values of the
states of vigilance and those of the powers of the various
EEG frequency bands with the Statistica 12 program
(StatSoft Inc., Tulsa, OK, USA). The baseline day data of
the control versus those of the lesioned rats and the baseline
versus NMDA day data of the control and lesioned animals
were compared by two- and three-way analysis of variance
(ANOVA) for repeated measures in the vigilance state and
power density data, respectively. In general, the F-statistics
are reported only for the treatment effect and the interactions
with the treatment effect when the differences proved to be
statistically signiﬁcant. The Tukey test was used for post-hoc
comparisons to test the effects of NMDA in the various 3-h
time bins. To test the inﬂuence of SAP lesioning on the
effects of NMDA, when NMDA induced signiﬁcant changes
(sleep: initial 3-h values, power density values: second and
third 3-h values), data were compared among the baseline
and NMDA days of the control (intact) and the SAP-lesioned
animals by means of two- and four-way ANOVAs for repeated
measures in the sleep and power density data, respectively.
Values of P < 0.05 were considered to be signiﬁcant.
RESULTS
Distribution of vigilance states
In the control (intact) animals, NMDA exhibited a robust arousal
effect during the perfusion of the drug (10–13 h, shown in
Fig. 2). The daily distributions of W, NREM and REM sleep
were changed signiﬁcantly (ANOVA, time of day 9 treatment
interaction; W: F(7,49) = 9.325, P < 0.05; NREM: F(7,49) =
9.692, P < 0.05; REM: F(7,49) = 4.645, P < 0.05). W was
enhanced (baseline day: 29.7  3.1%, NMDA day:
71.7  4.5%) and NREM (baseline day: 59.6  2.1%, NMDA
day: 26.0  4.0%) and REM (baseline day: 10.7  1.3,
NMDA day: 2.4  0.8%) were suppressed by NMDA in the
initial 3-h period, i.e. during the NMDA perfusion (Tukey:
P < 0.05). This arousal effect was followed by an opposite
reaction, resulting in the tendency to decrease in W and
increase in NREM and REM sleep.
The lesioning of the cholinergic structures in the BF by
SAP did not change the baseline sleep–wake activity
signiﬁcantly; nor was the arousing effect of NMDA modiﬁed
greatly. The daily distribution of W was changed (ANOVA, time
of day 9 treatment interaction: F(7,49) = 8.286, P < 0.05) and
W was enhanced by NMDA (ANOVA, F(1,7) = 7.735, P < 0.05),
the increase proving signiﬁcant in the initial 3-h period
(baseline day: 26.8  5.1%, NMDA day: 71.9  4.5%), i.e.
also in the lesioned animals during the NMDA perfusion
(Tukey: P < 0.05). The daily distribution of NREM and REM
sleep was also changed signiﬁcantly (ANOVA, time of
day 9 treatment interaction; NREM: F(7,49) = 13.681,
P < 0.05; REM: F(7,49) = 7.929, P < 0.05). NREM (baseline
day: 61.6  3.6%, NMDA day: 25.2  4.2%) and REM
(baseline day: 11.5  1.8%, NMDA day: 2.1  0.7%) were
also suppressed by NMDA in the initial 3-h period, i.e. during
the NMDA perfusion (Tukey: P < 0.05) in the lesioned rats. In
contrast to the changes in the control (intact) rats, in the
lesioned animals this arousal effect was not followed by an
opposite reaction immediately; the tendency to decrease in
W and increase in NREM and REM sleep was noted only
later.
As NMDA enhanced W and suppressed NREM and REM
sleep in the initial 3-h period (i.e. during the NMDA perfusion),
these 3-h values [baseline and NMDA days in the control
(intact) and the lesioned rats] were compared by ANOVA.
NMDA enhanced W (F(1,14) = 87.272, P < 0.05) and sup-
pressed NREM (F(1,14) = 84.815, P < 0.05) and REM
(F(1,14) = 47.756, P < 0.05), but the lesioning with SAP did
not inﬂuence these effects of NMDA signiﬁcantly (there were
no lesion 9 treatment interactions).
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Power spectrum analysis
In the control (intact) rats, NMDA perfusion did not result in
any signiﬁcant change in the power spectra of the EEG
during W (ANOVA); however, signiﬁcant alterations were found
during NREM sleep. The distribution of power across the
various frequency bands (ANOVA frequency band 9 treatment
interaction: F(4,28) = 4.615, P < 0.05) and the daily distribu-
tion of power in the various frequency bands (ANOVA, time of
day 9 treatment interaction: F(7,49) = 4.665, P < 0.05; time
of day 9 frequency band 9 treatment interaction: F(28,196) =
3.072, P < 0.05) were changed. Delta power was increased
signiﬁcantly during the third 3-h period (16–19 h in Fig. 3) of
the recording (Tukey: P < 0.05), i.e. following the suppres-
sion of sleep. Thus, during the NMDA perfusion only
tendency-like changes were noted; the most characteristic
was a tendency towards an increase in the high-frequency
theta band (which corresponds to the frequency range of the
rhythmic hippocampal theta activity) during W. A signiﬁcant
change, an increase in delta power during NREMS, was
observed only in the post-NMDA period, i.e. following the
suppression of sleep by NMDA.
The lesioning of cholinergic structures in the BF by SAP did
not change the baseline EEG power spectra signiﬁcantly
(ANOVA); nor were the effects of NMDA modiﬁed greatly.
During W, NMDA did not change the power density values
signiﬁcantly (ANOVA). During NREM sleep the daily distribution
of power in the various frequency bands were changed
(ANOVA, time of day 9 treatment interaction: F(7,49) = 8.83,
P < 0.05; time of day 9 frequency band 9 treatment inter-
action: F(28,196) = 6.258, P < 0.05). Theta power, in both the
low- and high-frequency theta bands, was increased in the
second 3-h period (13–16 h in Fig. 3) and delta, alpha and
beta powers were enhanced in the third 3-h period (16–19 h
in Fig. 3; i.e. signiﬁcant changes were noted in the post-
NMDA period; Tukey: P < 0.05).
Figure 1. (a) Probe tip locations. All probe tips were located between 0.26 and 0.80 mm from the bregma (Paxinos and Watson, 1998). The
circles indicate the locations of the probe tips; if more than one tip was located in the same place, only one representative circle is depicted;
open symbols: locations in control (intact) animals; closed black symbols: locations in lesioned animals; closed grey symbols: the same location
in a control (intact) and a lesioned animal. (b) Effect of saporin (SAP) treatment on the number of choline acetyltransferase (ChAT)-positive cells
in the basal forebrain (BF). On the SAP-treated side the number of ChAT-positive cells was 3.1% of that on the control side. CONT: control side;
SAP: SAP-treated side.
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Because, during NREM sleep, NMDA induced signiﬁcant
changes in the power of the individual frequency bands
during the second and third 3-h periods (i.e. in post-NMDA
periods), changes in power density values in these time-
periods were compared between the groups of control (intact)
and lesioned rats by ANOVA. The distribution of power
throughout the various frequency bands was changed by
NMDA (ANOVA, frequency band 9 treatment interaction:
F(4,56) = 38.633, P < 0.05; time of day 9 frequency
band 9 treatment interaction: F(4,56) = 3.755, P < 0.05), but
there was no statistical difference in this action between the
control (intact) and lesioned rats, and only some tendencies
to differ were noted. The enhancement of delta power by
NMDA tended to be greater in the control (intact) animals
than in the lesioned animals. In the lesioned rats the increase
in power appeared to be shifted a little to the lower frequency
bands. The enhancement of power in the theta, alpha and
beta ranges reached the level of statistical signiﬁcance only
in the lesioned rats (Fig. 3).
DISCUSSION
We have reported previously that the local administration of
SAP into the BF destroyed the cholinergic cells effectively
and selectively (Kalinchuk et al., 2008); now the same dose
of SAP was administered using exactly the same procedure.
The main ﬁnding of the present study was that speciﬁc
destruction of the BF cholinergic neurones by SAP did not
prevent cortical arousal induced by NMDA administration in
the BF, indicating that the effects of GLUT are mediated by
projection neurones other than the cholinergic ones.
Local administration of NMDA via microdialysis enhanced
W. Usually, administration of substances via microdialysis
effects tissues near the probe. The concentration of the
administered substance declines sharply with increasing the
distance from the probe. The BF is a relatively large brain
area, so we have reason to believe that NMDA acted locally
there. NMDA administered into the BF via another route
(microinjection) also has an arousing action (Cape and
Figure 2. Effects of N-methyl-D-aspartate (NMDA) perfusion on sleep–wake activity in control (intact) rats and after the selective lesioning of
the cholinergic cells in the basal forebrain (BF) by the microinjection of saporin (SAP). The horizontal grey bars at the top indicate the NMDA
perfusion (0.3 mM) in the BF on the NMDA day; cerebrospinal ﬂuid (CSF) was perfused on the control day. The curves display the daily patterns
of W, non-rapid eye movement (NREMS) and rapid eye movement (REMS) sleep. The data are computed for consecutive 3-h bins and
expressed as percentages of the recording time [mean values  standard error (SE)]. Open symbols: baseline (CSF) day; closed symbols:
NMDA day. The light and dark horizontal bars on the x-axis indicate light and dark phases, respectively. Asterisks denote signiﬁcant differences
from the baseline (Tukey, P < 0.05).
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Jones, 2000), and optogenetic and chemogenetic stimulation
of the BF cells can enhance W (Anaclet et al., 2015; Xu
et al., 2015; Zant et al., 2016). An increase in adenosine
level was detected during administration of NMDA into the BF
via microdialysis (Wigren et al., 2007). These lines of
evidence support the view that NMDA acted locally in the
BF, and the enhancement of W was due exclusively, or to a
large extent, to this local action. However, we could not
measure the NMDA concentrations in the tissues and thus
cannot exclude completely the possibility that low
concentrations of NMDA also reached brain areas outside
the BF. Intrahypothalamic administration of NMDA can also
enhance W (Kostin et al., 2014). Our ﬁndings of increased W
and decreased NREM and REM sleep by NMDA adminis-
tration in intact rats are consistent with our earlier observa-
tions (Wigren et al., 2007) and with those of Manfridi et al.
(1999) and Cape and Jones (2000), and they are also in line
with the role of glutamatergic transmission and the BF NMDA
receptors in the mediation of the effects of the ascending
activating system. Similarly to the awakening action of
Figure 3. Effects of N-methyl-D-aspartate (NMDA) perfusion on the vigilance-state speciﬁc electroencephalogram (EEG) power spectrum in
control (intact) rats and after the selective lesioning of the cholinergic cells in the BF by the microinjection of saporin (SAP). The horizontal grey
bars at the top indicate the NMDA perfusion. The curves display changes in the power of the various frequency bands compared to the
corresponding baseline values. The data are computed for consecutive 3-h bins and expressed as percentages of the baseline values [mean
values  standard error (SE)]. Open symbols: control (intact) rats; closed symbols: lesioned rats. The light and dark horizontal bars on the x-
axis indicate light and dark phases, respectively. Circles above the symbols denote signiﬁcant differences from the baseline; open circles:
control (intact) rats; closed circles: lesioned rats (Tukey, P < 0.05).
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NMDA, the cortical activation induced by the administration of
hypocretin into the BF was reported not to be abolished by
the destruction of the cholinergic neurones (Blanco-Centurion
et al., 2006).
Interestingly, similar experiments involving the administra-
tion of histamine (Zant et al., 2012) or a noradrenaline
agonist, methoxamine (Lelkes et al., 2013), into the BF
revealed that, while the administration of these drugs into
intact rats effectively induced cortical arousal, after destruc-
tion of the BF cholinergic cells with SAP these effects were
abolished, indicating that the arousing effects of both
histamine and noradrenaline are mediated by BF cholinergic
cells.
As shown by the present study, the integrity of the non-
cholinergic neurones in the BF is sufﬁcient for the induction
of cortical activation by NMDA. Cortically projecting
GABAergic and/or glutamatergic neurones in the BF may
mediate the arousing action of NMDA. While it appears that
cholinergic neurones are not essential in NMDA-induced
cortical arousal, there is clear evidence that GLUT regulates
the BF cholinergic cells: administration of GLUT agonists
into the BF activates the cholinergic cells (as shown by the
enhancement of c-Fos expression) and increases cortical
acetylcholine release, which correlates with the gamma
power in the EEG (Cape and Jones, 2000; Fournier et al.,
2004). Parvalbumin-containing GABAergic neurones in the
BF enhance W and are excited by cholinergic cells (Anaclet
et al., 2015; Xu et al., 2015; Yang et al., 2014). The W-
promoting action of BF cholinergic neurones is mediated by
cortically projecting BF non-cholinergic cells (Zant et al.,
2016). However, parvalbumin-containing GABAergic neu-
rones can also be excited directly by glutamatergic cells (Xu
et al., 2015). Thus, this can be an alternative route for
mediating the arousing action of GLUT without the contri-
bution of BF cholinergic neurones. The baseline sleep was
little affected by the BF cholinergic lesion. This ﬁnding is in
line with our earlier observation (Lelkes et al., 2013) and
also with that of Kaur et al. (2008), who reported only small
transient changes in sleep after BF SAP lesion. BF non-
cholinergic neurones alone are enough for maintaining
normal sleep–wake activity in baseline conditions when
sleep is not disturbed, but not for mediating all types of
arousing action from the ascending activating system. For
example, the integrity of the cholinergic structures in the BF
is important for mediation of the arousing effect of nora-
drenaline and histamine (Lelkes et al., 2013; Zant et al.,
2012).
All these lines of evidence support the view that both
cholinergic and non-cholinergic neurones in the BF operate
jointly in the control of cortical activation (Fuller et al., 2011)
and in mediation of the effects of the ascending activating
system.
The cholinergic neurones in the BF have a particular role
in the induction of recovery sleep. Recovery sleep is the
additional sleep experienced after a prolonged W period,
and is regarded as a sign of the homeostatic regulation of
sleep (Borbely, 1982). In response to a lesion that specif-
ically destroys the cholinergic cells in this area, a prolonged
W period is no longer able to induce increases in either
sleep duration or slow wave activity (Kalinchuk et al., 2008;
Porkka-Heiskanen et al., 1997). In the present study,
suppression of NREM and REM sleep by NMDA in the
intact rats was followed by an increase in EEG delta activity
during NREM sleep and rebound-like tendencies to increase
NREM and REM sleep shortly after cessation of the
deprivation. A similar increase in EEG delta activity follow-
ing administration of NMDA into the BF has already been
reported (Wigren et al., 2007). BF administration of NMDA
results in an increased release of adenosine (Wigren et al.,
2007), which may be involved in the mechanism of recovery
sleep (Porkka-Heiskanen et al., 1997). All these lines of
evidence indicate the activation of homeostatic regulatory
mechanisms. EEG delta activity was also enhanced in the
SAP-lesioned animals; however, no rebound-like tendencies
to increase sleep were observed immediately after the
suppression of sleep, though small compensatory increases
in NREM and REM sleep were noted later. In previous
studies with histamine and noradrenaline agonists, the
compensatory increases were abolished by the cholinergic
lesion in the histamine-treated animals (Zant et al., 2012;
personal communication), while some rebound-like tenden-
cies were still present after the lesion in the methoxamine-
treated animals (Lelkes et al., 2013). Observations that the
SAP lesion abolished the rebound-like increases of sleep
following histamine administration and the compensatory
tendency to increase sleep immediately after the NMDA-
induced sleep suppression are in line with the role of BF
cholinergic cells in the homeostatic sleep regulatory mech-
anisms. However, the presence of enhancement in delta
power, the late tendency to compensatory increase in sleep
following the NMDA-induced sleep suppression and the
tendency to compensatory increase in sleep following the
methoxamine-induced sleep suppression in the lesioned
rats may indicate that non-cholinergic mechanisms are also
involved in the mechanism of recovery sleep.
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